Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02818751 · ClinicalTrials.gov registry record · NA

Neurofunctional Predictors of Escitalopram Treatment Response in Adolescents With Anxiety

A NA study, sponsored by University of Cincinnati.

Completed
Registry status
NA
Development phase
84
Enrollment target

NCT02818751 is a NA study that has completed, run by University of Cincinnati. The registered enrollment target is 84 participants.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT02818751, a NA study, has completed, sponsored by University of Cincinnati.

COMPLETED
Registry status
NA
Development phase
84 participants
Enrollment target

Study Summary

Neurofunctional Predictors of Escitalopram Treatment Response in Adolescents with Anxiety. To determine the effects of escitalopram on functional activation patterns during a Continuous Performance Task with Emotional and Neutral Distracters, the CPT-END. To examine baseline functional activity and functional connectivity profiles in the ventrolateral prefrontal cortex as markers of subsequent treatment response to escitalopram in adolescents with generalized anxiety disorder (GAD). To use proton magnetic resonance spectroscopy (1H MRS) to examine glutamatergic and γ-aminobutyric acid (GABA)-related abnormalities in the anterior cingulate in adolescents with GAD as compared to healthy adolescents.

Interventions

  • OTHER Placebo
  • DRUG Escitalopram

Trial Details

FieldValue
Enrollment Target 84 participants
Start Date 2015-05
Est. Completion 2020-05
Phase NA

Sponsor

University of Cincinnati

245 total trials

What the Registry Record Tells You About NCT02818751

The ClinicalTrials.gov registry entry for NCT02818751 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 84 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Cincinnati, which has 245 total studies on file at ClinicalTrials.gov.

The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.

NCT02818751 reports 0 study locations.

Frequently Asked Questions

What is clinical trial NCT02818751 about?

NCT02818751 is a clinical study titled "Neurofunctional Predictors of Escitalopram Treatment Response in Adolescents With Anxiety". Neurofunctional Predictors of Escitalopram Treatment Response in Adolescents with Anxiety. To determine the effects of escitalopram on functional activation patterns during a Continuous Performance Task with Emotional and Neutral Distracters, the CPT-END. To examine baseline functional activity and ...

What is the current status of trial NCT02818751?

This trial is currently completed. It is a NA study. The enrollment target is 84 participants. The study started on 2015-05. Estimated completion is 2020-05.

What interventions are being tested in trial NCT02818751?

The interventions under investigation include: Placebo (OTHER), Escitalopram (DRUG).

Who is sponsoring clinical trial NCT02818751?

This trial is sponsored by University of Cincinnati, which has 245 total clinical trials registered on ClinicalTrials.gov.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.